Prompted by Mayim Bialik's reaction to one dose, the doctors say evidence is promising for IBD but limited overall, and GLP-1s shouldn't replace autoimmune care.
Recap by typeshit. Full story at Healthline.
Some people on weight loss drugs are testing lower doses, hoping for fewer side effects. ThePrint reports on the trend, which these users describe themselves.
Bell raises the question of muscle loss for people losing weight on a GLP-1 and notes it isn't medical advice, pointing viewers to their doctor.
Dr. Woo points to the official position of the AAO and NANOS on whether routine eye exams just to check for NAION are needed.
USA TODAY covers the copycat GLP-1 crackdown, from the Apothecary Pharma recall to an import alert on a Chengdu factory. Novo says it has filed over 130 lawsuits.
STAT
Members of Congress from both parties want the FDA to stop imports of copycat versions of Eli Lilly's experimental obesity drug, which is still in trials.
PennLive reports regulators bumped the risk class on a GLP-1 recall involving an ingredient linked to Mounjaro and Zepbound. Details are at the link.
Loading…